Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Fulvestrant in Hormone Refractory Prostate Cancer
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT00476645
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00454805
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT00451555
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00423917
- Locations
- 🇺🇸
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States
🇺🇸Northwest Ohio Oncology Center, Maumee, Ohio, United States
🇺🇸Mount Carmel Health - West Hospital, Columbus, Ohio, United States
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT00405938
- Locations
- 🇺🇸
Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 295
- Registration Number
- NCT00390455
- Locations
- 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸University of Maryland Shore Medical Center at Easton, Easton, Maryland, United States
🇺🇸Saint Vincent Healthcare, Billings, Montana, United States
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00372996
- Locations
- 🇦🇷
Instituto de Investigaciones Clinicas, Rosario, Santa Fe, Argentina
🇧🇪UZ Gasthuisberg, Medische Oncologie, Leuven, Belgium
🇦🇷Centro Oncologico Rosario, Rosario, Santa Fe, Argentina
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT00357110
- Locations
- 🇳🇴
Research SIte, Porsgrunn, Norway
🇳🇴Research Site, Trondheim, Norway
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
- Conditions
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00334295
- Locations
- 🇩🇪
Research Site, Rostock, Germany
Faslodex Advanced Breast Cancer Local Chinese Study
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT00327769
- Locations
- 🇨🇳
Research Site, Xi AN, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.